Allos Therapeutics to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
23 Julho 2008 - 9:00AM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company focused on developing and commercializing innovative small
molecule drugs for the treatment of cancer, today announced that
members of the Company�s senior management will present a corporate
overview at the Bank of America 2008 Specialty Pharmaceuticals
Conference in Southampton, New York. The Company�s presentation
will take place at 3:50 p.m. (Eastern) on Thursday, August 7, 2008.
There will be a live webcast of the presentation, which will be
accessible through a link posted on the Allos website home page and
investor relations section. The webcast will be available for
replay on Allos� website through August 22, 2008. About Allos
Therapeutics, Inc. Allos Therapeutics is a biopharmaceutical
company focused on developing and commercializing innovative small
molecule drugs for the treatment of cancer.�The Company's lead
product candidate, PDX (pralatrexate), is a novel antifolate
currently under evaluation in a pivotal Phase 2 (PROPEL) trial in
patients with relapsed or refractory peripheral T-cell lymphoma.
The PROPEL trial is being conducted under an agreement reached with
the U.S. Food and Drug Administration under its special protocol
assessment, or SPA process. The Company is also investigating PDX
in patients with bladder cancer, non-small cell lung cancer and a
range of lymphoma sub-types.�The Company's other product
candidate�is RH1, a targeted chemotherapeutic agent currently being
evaluated in a Phase 1 trial in patients with advanced solid tumors
or non-Hodgkin�s lymphoma (NHL). Allos currently retains exclusive
worldwide rights to PDX and RH1 for all indications. For additional
information, please visit the Company�s website at www.allos.com.
Safe Harbor Statement The anticipated presentation will contain
forward-looking statements that involve significant risks and
uncertainties. Additional information concerning these
forward-looking statements and other factors that may cause actual
results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2007 and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in the presentation. All
forward-looking statements are based on information currently
available to the Company on the date thereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics, Inc.